This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the fifth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

This story is part of a larger series on viroids and virusoids, small infectious RNAs. It is also the sixth installment in a series on hepatitis D virus, a virusoid-like pathogen that causes serious ...

Aligos Therapeutics Inc. has divulged bicyclic compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) and hepatitis D virus infections.

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...

In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV). Now real-world studies of patients ...